TABLE 1.
Non‐FLT3 amp (n = 1993) | FLT3 amp (n = 85) | P a | P b | ||
---|---|---|---|---|---|
Low amp (n = 40, 1.9%) n (%) | High amp (n = 45, 2.2%) n (%) | ||||
Age | |||||
Median, (range) (y) | 64 (21‐88) | 65 (35‐84) | 65 (32‐83) | .85 | .88 |
Gender | |||||
Male | 1103 (55.3) | 29 (72.5) | 21 (46.7) | .56 | .02 |
Female | 90 (44.7) | 11 (28.5) | 24 (54.3) | ||
Primary site | |||||
Right colon | 619 (31.1) | 11 (27.5) | 13 (28.9) | <.01 | .06 |
Left colon | 718 (36.0) | 15 (37.5) | 12 (71.1) | ||
Rectum | 628 (31.5) | 10 (25.0) | 20 (44.4) | ||
Unknown | 28 (1.4) | 4 (10.0) | 0 (0.0) | ||
Histology (grade) | |||||
Grade 1 | 543 (27.2) | 8 (20.0) | 9 (20.0) | .20 | .75 |
Grade 2 | 1201 (60.3) | 26 (65.0) | 33 (73.3) | ||
Grade 3 | 94 (4.7) | 3 (7.5) | 1 (2.2) | ||
Others | 23 (5.2) | 2 (5.0) | 1 (2.2) | ||
Unknown | 52 (2.6) | 1 (2.5) | 1 (2.2) | ||
RAS | |||||
Wild‐type | 1149 (57.2) | 16 (40.0) | 28 (63.2) | .12 | .04 |
Mutant | 844 (42.8) | 24 (60.0) | 17 (37.8) | ||
BRAF V600E | |||||
Wild‐type | 1869 (93.8) | 39 (97.5) | 45 (100.0) | .03 | .29 |
Mutant | 124 (6.2) | 1 (2.5) | 0 (0.0) | ||
PIK3CA | |||||
Wild‐type | 1763 (88.4) | 36 (90.0) | 44 (97.8) | .14 | |
Mutant | 230 (7.3) | 4 (10.0) | 1 (2.2) | .13 | |
ERBB2 | |||||
Non‐Amp | 1938 (97.2) | 39 (97.5) | 45 (93.3) | .37 | .29 |
Amp (CN ≥ 7.0) | 55 (2.8) | 1 (5.0) | 0 (0.0) | ||
TP53 | |||||
Wild‐type | 711 (35.7) | 11 (27.5) | 11 (24.5) | .16 | .75 |
Mutant | 1282 (64.3) | 29 (72.5) | 34 (75.5) | ||
BRCA1 | |||||
Wild‐type | 1859 (93.2) | 31 (77.5) | 38 (80.0) | <.01 | .41 |
Mutant | 134 (6.8) | 9 (22.5) | 7 (15.6) | ||
BRCA2 | |||||
Wild‐type | 1731 (86.9) | 30 (75.0) | 44 (97.8) | <.01 | <.01 |
Mutant | 262 (13.1) | 0 (0.0) | 0 (0.0) | ||
Amp (CN ≥ 7.0) | 0 (0.0) | 10 (25.0) | 1 (2.2) |
Abbreviations: amp, amplification; CN, copy number.
P‐values were calculated including 3 cohorts (Non‐FLT3 amp and FLT3 amp: Low amp and high amp) using Pearson chi‐square test.
P‐values were calculated between 2 cohorts (Low amp and high amp) by Pearson chi‐square test.